What's at stake: Aroa has been long on promise and short on delivery. This result suggests that may be changing for the better.
Background: Aroa listed on the ASX in 2020 with the shares at A75 cents. They surged to A$1.40 on debut but have never surpassed that. Even with today's jump, the shares are at A54 cents.
Main players: Brian Ward, Aroa founder and CEO. Retail investors who hold 46% of the company.
Shares in New Zealand-based and ASX-listed medical technology company Aroa Biosurgery spiked by almost 15% in morning trade today after the company rewarded the patience of investors with a full year profit.
Aroa’s announced full year ebitda of $4.2m for the year to the end of March, ahead of the
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Key points
What's at stake: Aroa has been long on promise and short on delivery. This result suggests that may be changing for the better.
Background: Aroa listed on the ASX in 2020 with the shares at A75 cents. They surged to A$1.40 on debut but have never surpassed that. Even with today's jump, the shares are at A54 cents.
Main players: Brian Ward, Aroa founder and CEO. Retail investors who hold 46% of the company.
